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Introduction: Oral or intravenous (IV) paracetamol (APAP) is used 
for mild to moderate pain but has a latency to be effective. When fast 
relief is required and oral/IV routes are not available because of the 
patient’s condition, the transmucosal buccal route may be an alterna-
tive. A new transmucosal buccal (b) pharmaceutical form of APAP 
that had been previously assessed in healthy volunteers is studied in 
patients admitted to hospital for acute pain.
Patients (or Materials) and Methods: A randomized double-
blind noninferiority clinical trial (NCT01586143) included 38 
patients admitted to the Accident and Emergency Department of 
Clermont-Fd University Hospital, France, for trauma of the upper 
or lower limb, and with pain intensity between 4 and 6 on a 0 to 10 
numerical scale (NS). Patients were injected at t0 over a 15-minute 
period with placebo (0.9% saline) or APAP (1 g) and concomitantly, 
125 mg of APAP dissolved in 1 mL of an hydroalcoholic solution 
(HAS) or placebo (HAS only) was applied in the left mucogingival 
sulcus. Patients were asked not to swallow for 1:30 minutes. NS 
evaluations were done at t10, t30, t120, and t180 minutes after 
administration. Primary end point was the pain intensity difference 
(PID) between t30 min and t0. PID of both arms were compared 
by Student t test with a P < 0.05 significance. Secondary end points 
were PID at other times.
Results: Results (mean [SD]) show no significant PID difference 
between bAPAP and ivAPAP, respectively: t10min (–0.9 [1.3] vs –1.3 
[1.8]), t30min (–2.0 [1.8] vs –2.4 [1.5]), t120min (–2.9 [1.9] vs –3.3 
[1.5]), t180 (–2.1 [2.2] vs –3.4 [1.8]; all P > 0.05).
Conclusion: Transmucosal buccal APAP has a similar analgesic effect 
than ivAPAP in patients admitted to hospital for acute trauma pain of 
mild to moderate intensity. The mechanism of action of this pharma-
ceutical form must now be studied further. This attractive alternative 
to other routes would be useful in situations where oral or IV routes 
are not available or in vulnerable populations (cancer pain, palliative 
care, geriatrics) for acute pain paroxysms.
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Introduction: The calcineurin inhibitor (CI) tacrolimus remains the 
mainstay of kidney transplant maintenance immunosuppression. In 
most patients, it is combined with mycophenolate mofetil (MPA) and 
corticosteroids. As part of an investigation of effect of drug–drug 
interactions in the setting of routine care, we investigated the effect 
of mycophenolate mofetil dose on the kinetics of tacrolimus.
Patients (or Materials) and Methods: We performed a retrospective 
analysis of TDM measurements in the past 5 years at a single trans-
plant center in the University Hospital in Olomouc, Czech Republic. 
More than 4000 measurements of trough concentrations (C0) of CIs 
and MPA were included in the analysis made in 111 male and 70 
female kidney transplant recipients (181 in total). Patients were aged 
13 to 72 years (average, 45.7). Average time from transplant was 5.6 
years (0.4 to 18).
Drug measurements were obtained from the hospital informa-
tion system, and information on prescription was ascertained from 
prescription database and patient clinical records (including dosing 
instructions and specific temporary instructions concerning co-pre-
scription of interacting medication). CI levels were expressed as nor-
malized dose (ND) required to reach a unit concentration and a linear 
regression model was constructed to quantify effects of various inter-
acting factors (eg, age, sex, prednisone dose, MPA dose, body weight).
Tacrolimus ND = a0-a1 × MPA + a2 × Tx-a3 × ATB-a4 × 
INTER + a5 × DOSE-a6 × AGE
Where MPA is the dose of mycophenolate mofetil in mg/kg body 
weight, Tx is time from transplantation in years, ATB is 1 if the 
patient is treated with an antimicrobial, INTER is 1 is the patient is 
treated with an interacting antimicrobial, DOSE is the dose of tac-
rolimus in μ g/kg of body weight, and AGE is patient’s age in years.
Results: The constructed model yielded the following statistically 
significant parameters: The coefficient for MPA dose means that for 
each 100 mg of MPA there was on average a 0.99 l/kg reduction in 
the dose of tacrolimus to reach a unit concentration (14%). Other 
significant factors included time from transplantation, interacting 
antimicrobials, and age (all, P < 0.001). 
Conclusion: Our data from routine clinical practice indicate the pres-
ence of a mycophenolate-mofetil and tacrolimus interaction. Some 
literature reports confirm this interaction, but data are still conflict-
ing, and more studies are needed to confirm its clinical significance.
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Introduction: According to the product information of imatinib, 
imatinib is mainly metabolized by CYP3A4. Because our recent 
in vitro findings indicate that CYP2C8 participates in imatinib 
N-demethylation2 and there are no clinical data concerning the role 
of CYP2C8 in its metabolism, we studied the effects of the strong 
CYP2C8 inhibitor gemfibrozil on the single-dose pharmacokinetics 
of imatinib in healthy volunteers.
Patients (or Materials) and Methods: In a randomized, crossover 
study, 10 healthy subjects were administered gemfibrozil 600 mg 
or placebo twice daily for 6 days, and imatinib 200 mg on day 3. 
The plasma concentrations of imatinib and its main metabolite 
N-desmethylimatinib (N-DMI) were determined using a liquid chro-
matography–tandem mass spectrometry system. The pharmacokinet-
ics of imatinib and N-DMI were calculated by noncompartmental 
analysis. Logarithmic transformation was used for pharmacokinetic 
variables, and statistical comparisons between the phases were made 
with the paired t test. Because imatinib may time dependently inhibit 
its own CYP3A4-mediated elimination,3 the obtained clinical data 
was then applied to a physiologically based pharmacokinetic (PBPK) 
model to predict the contribution of CYP2C8 to imatinib metabolism 
during multiple-dose administration.
Estimate Std. Error Significance
a0 (Intercept) 7.090e-03 1.965e-04 P < 0.001
a1 (MPA) –9.978e-04 1.326e-04 P < 0.001
a2 (Tx) 2.128e-04 1.890e-05 P < 0.001
a3 (ATB) –5.921e-04 2.644e-04 P < 0.01
a4 (INTER) –2.557e-03 5.149e-04 P < 0.001
a5 (DOSE) 1.522e-04 3.059e-06 P < 0.001
a6 (AGE) –2.533e-05 6.984e-06 P < 0.001
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Results: Gemfibrozil unexpectedly reduced the peak plasma con-
centration (Cmax) of imatinib by 35% (P < 0.001). Gemfibrozil also 
reduced the Cmax and area under the plasma concentration–time curve 
(AUC0–∞) of N-DMI by 56% and 48% (P < 0.001), while the AUC0–∞ 
of imatinib was unaffected. Furthermore, gemfibrozil reduced the 
Cmax/C24 h ratios of imatinib and N-DMI by 44% and 17% (P < 
0.05), suggesting diminished daily fluctuation of imatinib plasma 
concentrations during concomitant use with gemfibrozil. PBPK simu-
lations suggested an increased contribution (70%) for CYP2C8 to the 
hepatic metabolic clearance of imatinib during long-term treatment 
with the most common imatinib dosing, 400 mg once daily. The 
impaired imatinib absorption observed during the gemfibrozil phase 
was best explained by inhibition of an intestinal influx transporter 
involved in imatinib absorption.
Conclusion: This study shows for the first time that CYP2C8 is 
important in the metabolism of imatinib in humans, and that an 
influx transporter may be relevant for imatinib absorption in vivo. 
Given that the efficacy and adverse effects of imatinib are dose-
dependent, care is warranted when gemfibrozil is used in combina-
tion with imatinib.
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Introduction: There are still controversies over pill substitution 
among AEDs: some studies claimed that switching between brand 
and generic AED (generic substitution) can lead to breakthrough 
seizures; other studies have refuted these concerns. France and some 
US states recommend limiting substitution of generic AED. We aimed 
at further estimating the association between generic substitution and 
loss of seizure control.
Patients (or Materials) and Methods: We used data from the French 
National Health Insurance Information System linked with the 
French Hospital Discharge Database to identify a cohort of patients 
aged 18 years or more who filled a prescription in 2010 for AED 
that had at least 1 brand-name and 1 generic form available on the 
French market (carbamazepine, lamotrigine, levetiracetam, oxcar-
bazepine, topiramate, or valproic acid). Patients with a medical his-
tory of stroke or cancer and women who gave birth (ICD-10 codes, 
O80–O84) were excluded. We used a case-crossover design to assess 
the relationship between seizure-related hospitalization and generic 
substitution. For this preliminary analysis, cases were identified as 
individuals with a seizure-related hospitalization between July 2010 
and December 2010 (ICD-10 codes, G40 or G41). The index date 
was defined as the date of first occurrence in the inpatient file of the 
codes of interest pending a preceding hospitalization-free period of at 
least 6 months with regular dispensations of targeted AED. The case 
period corresponded to the 3 months preceding the index date; the 
control period was defined as the 3 months immediately preceding the 
case period. Generic substitution was defined as a filled prescription 
for a generic AED that was preceded by a filled prescription for a 
brand-name counterpart. Matched odds ratio estimates were based 
on the ratio of discordant pairs of case and control periods in regard 
to generic substitution; ORs and 95% CIs were estimated using con-
ditional logistic regression model. All analyses were conducted using 
the SAS statistical package (version 9.2; SAS Institute).
Results: The cohort included 566,549 adult patients filling targeted 
AED. We identified 10,089 patients with eligible seizure-related hos-
pitalization in the second half of 2010, excluding stroke, cancer, and 
childbirth. Among them, 2980 had regular dispensations. Generic 
substitution was observed in 461 patients, 273 in the case period and 
258 in the control period; matched OR = 1.08 (95% CI, 0.88–1.32).
Conclusion: Generic substitution was not associated with an elevated 
risk of seizure-related hospitalization.
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Introduction: Studies have shown that the cloned enzyme donor 
immunoassays (CEDIA) for buprenorphine, methadone, and 2-eth-
ylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) might be suit-
able for drugs-of-abuse testing in urine, but sensitivity, specificity, 
and optimal cutoff are to be determined. The aim of this study was 
to evaluate the overall performance of CEDIA compared with liquid 
chromatography tandem mass spectrometry (LC-MS/MS) for analy-
sis of buprenorphine, methadone, and EDDP in urine.
Patients (or Materials) and Methods: All urine samples sent to the 
Laboratory of Clinical Biochemistry at the Haukeland University 
Hospital for drugs-of-abuse testing in a period of 4 weeks in 
November–December 2011 were consecutively analyzed with both 
CEDIA and LCMSMS. Samples were from heroin-addicted patients 
enrolled in medication-assisted rehabilitation (MAR), treated with 
either buprenorphine or methadone, and from patients who were not 
treated with these drugs (non-MAR).
Results: A total of 2272 urine samples were included in the study; 
996 urine samples (43% of all samples) were from patients enrolled 
in MAR. The CEDIA assay for methadone, EDDP, and buprenorphine 
had a sensitivity of 97.4%, 98.8%, and 100% and a specificity of 
100%, 100%, and 98.0%, respectively. All samples with false-negative 
results in the CEDIA EDDP assay had also false-negative results in the 
methadone assay. A change in the CEDIA buprenorphine assay cutoff 
from the manufacturer’s recommendation on 5 ng/mL to 10 ng/mL 
gave a better specificity, with a reduction from 32 to 5 false-positive 
results. Most of the false-positive results in the CEDIA buprenorphine 
assay could be explained by cross-reactivity with codeine and mor-
phine but in concentrations lower than previously reported.
Conclusion: The CEDIA assays for buprenorphine and EDDP are 
suitable as screening methods for drugs-of-abuse testing in urine. The 
methadone assay did not provide additional information to the EDDP 
assay and may be redundant. We propose a cutoff concentration 
of 10 ng/mL for the CEDIA buprenorphine assay. Cross-reactivity 
